<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- March 27 2023 Personnel Change of ASKA Pharmaceutical
- March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical
- February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology
- December 28 2022 ASKA Pharmaceutical Obtains the Additional Approval of an Indication of FREWELL® COMBINATION TABLETS LD/ULD “ASKA” for the Infertility Treatment
- September 30 2022 ASKA Pharmaceutical Holdings Participates at 1st Femtech Tokyo
- September 30 2022 ASKA Pharmaceutical Terminates Joint Research and Development Agreement with RIBOMIC
- September 26 2022 Personnel Changes of ASKA Pharmaceutical
- August 26 2022 Organizational and Personnel Changes of ASKA Pharmaceutical
- July 19 2022 ASKA Pharmaceutical Signs a Co-promotion Agreement with Melody International for “Fetal Monitor iCTG” in Japan
- June 30 2022 ASKA Pharmaceutical donates its medicine to Ukraine
- June 28 2022 Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries
- June 23 2022 Agreement for Drospirenone
- June 16 2022 ASKA Pharmaceutical launches DroEthi® COMBINATION TABLETS for the treatment of Dysmenorrhea
- April 1 2022 Notice regarding Commencement of Insurance Coverage of ASKA Pharmaceutical drugs for the Indication of Infertility Treatment
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.